Новости за 14.03.2024

Good morning from Paul amp; Graham! Explanatory notes - A quick reminder that we don’t recommend any stocks. We aim to review trading updates amp; results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take amp; nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment. Читать дальше...

Good morning from Paul amp; Graham! Explanatory notes - A quick reminder that we don’t recommend any stocks. We aim to review trading updates amp; results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take amp; nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment. Читать дальше...

In a recent piece in the Academy, I went back to basics and explained how – and why – the StockRanks can be a useful tool for finding good shares and building a portfolio. This week I’m going to follow this up with a look at some of the top-ranked stocks in the UK market right now. My aim is to highlight possible opportunities, but also to show how the StockRanks sometimes highlight shares that I might not normally consider. This is one of the big advantages of a systematic approach, in my view ... Читать дальше...

Good morning from Paul amp; Graham! The Week Ahead - just published (by Roland this week) - the excellent new macro/large cap editorial here on Stockopedia. Mello Monday - starts at 17:00 today, with a talk I don't want to miss from Vin Murria at the start. Also React (LON:REAT) are on, which I think looks to have interesting potential, I was pleasantly surprised at some of the numbers when I last reviewed it recently. Although it has an ongoing challenge with lowly rated equity meaning it can't... Читать дальше...

Monash IVF (ASX:MVF) provides assisted reproductive services (ARS) and associated services such as ultrasounds and genetic testing. It has 23 ARS clinics across Australia and four service centres. There are 15 ultrasound clinics and two genetics laboratories. Monash has grown to now account for 21% market share for stimulated cycles in Australia and 20% market share for frozen embryos. Monash was included in the inaugural NAPS ANZ portfolio which commenced on 1 Jan 2023. When the portfolio was reset on 1 Jan 2024... Читать дальше...